AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice

Vaccine

Volumn 28, Issue 18, 2010, Pages 3076-3079

  Caillet, Catherine ^a   Piras, Fabienne ^a   Bernard, Marie Clotilde ^a   de Montfort, Aymeric ^a   Boudet, Florence ^a   Vogel, Frederick R ^a   Hoffenbach, Agnès ^a   Moste, Catherine ^a   Kusters, Inca ^a  

^a SANOFI PASTEUR   (France)

Author keywords

AF03 adjuvant; H1N1 pandemic vaccine; Immunogenicity

Indexed keywords

AF 03; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNOREACTIVITY; INFECTION RESISTANCE; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LOW DRUG DOSE; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; VACCINATION;

EID: 77949657463     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.050     Document Type: Article

References (18)

1. Swine influenza A (H1N1) infection in two children-Southern California March-April 2009. MMWR Morb Mortal Wkly Rep 58 15 (2009) 400-402
2. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325 5937 (2009) 197-201
3. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 58 RR-10 (2009) 1-8
4. Potter C.W., and Jennings R. Effect of priming on subsequent response to inactivated influenza vaccine. Vaccine 21 (2003) 940-945
5. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoché M.K., and Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 375 9708 (2010) 41-48
6. Kendal A.P., Pereira M.S., and Skehel J.J. Hemagglutination inhibition. Concepts and procedures for laboratory-based influenza surveillance (1982), US Department of Health and Human Services and Pan-American Health Organization, Atlanta, GA B17-B35-9
7. Rowe T., Abernathy R.A., and Hu-Primmer J. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 (1999) 937-943
8. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., and Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115 (2003) 63-73
9. Eichelberger M, Golding H, Hess M, Weir J, Subbarao K, Luke CJ et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, December 10-11, 2007; Vaccine 2008; 26(34):4299-303.
10. Greenberg M.E., Lai M.H., Hartel G.F., et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine-preliminary report. N Engl J Med 361 (2009) 1-11
11. Dormitzer P.R., Rappuoli R., Casini D., O'hagan D., Runham C., Montomoli E., et al. Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. Version 2. PLoS Curr: Influenza (2009) RRN1025
12. Hagenaars N., Mastrobattista E., Glansbeek H., Heldens J., van den Bosch H., Schijns V., et al. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 26 51 (2008) 6555-6563
13. Dolin R., Wise T.G., Mazur M.H., Tuazon C.U., and Ennis F.A. Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults. J Infect Dis 136 Suppl. (1977) S435-S442
14. De Groot A.S., Ardito M., McClaine E.M., Moise L., and Martin W.D. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 27 42 (2009) 5740-5747
15. Deliyannis G., Jackson D.C., Dyer W., Bates J., Coulter A., Harling-McNabb L., et al. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine 16 20 (1998) 2058-2068
16. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
17. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198 5 (2008) 642-649
18. Fauci A. US puts flu vaccines on trial interview by Declan Butler. Nature 460 7255 (2009) 562